RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of the Year ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition where PRA captured six individual awards, including two gold (Experienced CRA and Strategic Partnership—PRA and CytRx).
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e7bb36ae-d0f8-4c67-9e5d-bc1115531e72
“PRA is honored to receive this prestigious recognition,” said Sean Leech, Executive Vice President, Product Registration (Europe, Asia Pacific and Africa). “This award speaks to the passion and professionalism PRA employees bring to their clinical development work. We are extremely proud of this accomplishment.”
PRA also swept the Clinical Trial Administrator category winning gold, silver and bronze awards. Individual gold award recipients include:
- Clinical Trial Administrator: Irina Teslenko (Spain)
- Project Manager: Petra Croon (Belgium)
- Strategic Partnership Team (PRA and Bayer): Nicole Duffey (US), Kish Khan (UK)
Organized by PharmaTimes, the annual International Clinical Researcher of the Year competition provides a unique opportunity for clinical researchers from all over the world to benchmark their competencies and skills against their peers in an international learning environment. Designed and judged by an independent steering committee of high-level industry leaders, the International Clinical Researcher of the Year has categories for clinical researchers and teams at all stages of their career.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.